论文信息 - Phase I Trial of the Targeted Alpha-Particle Nano-Generator Actinium-225 (225Ac)-Lintuzumab (Anti-CD33; HuM195) in Acute Myeloid Leukemia (AML) - 字舞流文

Phase I Trial of the Targeted Alpha-Particle Nano-Generator Actinium-225 (225Ac)-Lintuzumab (Anti-CD33; HuM195) in Acute Myeloid Leukemia (AML)

S. Larson | P. Maslak | D. Scheinberg | M. McDevitt | J. Carrasquillo | M. Frattini | N. Pandit-Taskar | J. Jurcic | T. Rosenblat | S. Chanel | D. Cicic | K. Zikaras